Additionally, the anticancer activity of anti-CD47 antibodies depends on CS1 glycoprotein antigen (SLAMF7) phagocytic signaling, which is generally absent in solid cancers but is expressed in hematological malignancies (86, 92). Here, CD47 is linked to hematologic disorder.